European Pharmaceutical Review

DECEMBER 15, 2023

Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. Keytruda is an immunotherapy that works by increasing the ability of the body’s immune system to help detect and fight tumour cells.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

Pharmaceutical Technology

OCTOBER 14, 2022

German pharmaceutical firm Merck has extended its partnership with Moderna to jointly develop and sell mRNA-4157/V940, an investigational personalised cancer vaccine (PCV). They subsequently expanded the collaboration to include the development of antigen mRNA cancer vaccines in 2018.

Vaccines 115

Vaccines Research Laboratories Immunity Immunization 115

Pharmaceutical Technology

JUNE 23, 2022

The US Food and Drug Administration (FDA) has granted approval for Merck's (MSD outside the US and Canada) pneumococcal 15-valent conjugate vaccine, Vaxneuvance, for use in children aged six weeks to 17 years. The post US FDA grants approval for Merck’s pneumococcal vaccine for children appeared first on Pharmaceutical Technology.

Vaccines 59

Vaccines Immunity Immunization Research Laboratories 59

European Pharmaceutical Review

JUNE 28, 2024

Taly Dvorkis Fieldfisher QA/QC MICROBIOLOGY IN DEPTH FOCUS Implementing single temperature incubation Guillaume Pinon Laboratoires SERVIER Industrie Endotoxin standards: reflection and recommendation Dr Radhakrishna Tirumalai Merck Research Laboratories (MRL) Karen Zink McCullough MMI Associates, LLC Improving aseptic connections throughout the manufacturing (..)

Research Laboratories 52

Research Laboratories Vaccines Drug Development Immunity 52